Follow-The-Filings

Security · featured owners

GSK Gsk PLC

SPONSORED ADR Equity as of 2026 Q2 among managers we track

  • 8 Owners
  • #150
  • Max 3.5%
  • Master 0.15%
  • $2.6B
  • 1 add 6 reduce

Who owns this now

Largest portfolio weights among featured holders · max 3.5% (Hillman Capital Management) · not free-float ownership

  1. Hillman Capital Management reduce 3.5%
  2. Michael Krensavage 1.9%
  3. Dodge & Cox reduce 1.3%
  4. Kahn Brothers Group reduce 1.3%
  5. Tweedy, Browne Co. reduce 0.32%
  6. Murray Stahl reduce 0.01%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Dodge & Cox 2026 Q2 1.3% Reduce −17.8% 48,197,514 $2.5B history
Kahn Brothers Group 2026 Q2 1.3% Reduce −1.6% 158,438 $8M history
Michael Krensavage - Krensavage Asset Management 2026 Q2 1.9% Hold 96,729 $5M history
Hillman Capital Management 2026 Q2 3.5% Reduce −5.2% 92,383 $5M history
Tweedy, Browne Co. 2026 Q2 0.32% Reduce −0.3% 81,527 $4M history
Richard Pzena - Pzena Investment Management 2026 Q2 <0.01% Add +30.2% 24,507 $1M history
Murray Stahl - Horizon Kinetics Asset Management 2026 Q2 0.01% Reduce −1.5% 24,046 $1M history
Sarah Ketterer - Causeway Capital Management 2026 Q2 <0.01% Reduce −35.5% 7,163 $375K history

8 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 25 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
424B2 Filing Doc
6-K Filing Doc
6-K TOTAL VOTING RIGHTS Filing Doc
6-K MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER Filing Doc
6-K FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K TOTAL VOTING RIGHTS Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K 2ND QUARTER RESULTS Filing Doc
6-K HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ Filing Doc
6-K NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE Filing Doc
6-K ADMISSION TO TRADING Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS Filing Doc
6-K BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE Filing Doc
6-K CAMLIPIXANT PHASE III RESULTS UPDATE Filing Doc
6-K AUDIT TENDER CONCLUSION Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K GSK COMPLETES ACQUISITION OF NUVALENT, INC Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc

Updated about 18 hours ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K

newly public · no 10-K financials yet · 424B2

ownership over time

filing count by report period · click a bar for that quarter’s holders